SG11201909161PA - Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use - Google Patents
Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useInfo
- Publication number
- SG11201909161PA SG11201909161PA SG11201909161PA SG11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA
- Authority
- SG
- Singapore
- Prior art keywords
- dimethoxyquinolin
- fluorphenyl
- dicarboxamide
- cyclopropane
- oxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762511714P | 2017-05-26 | 2017-05-26 | |
PCT/US2018/034784 WO2018218233A1 (en) | 2017-05-26 | 2018-05-26 | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909161PA true SG11201909161PA (en) | 2019-10-30 |
Family
ID=62683441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909161P SG11201909161PA (en) | 2017-05-26 | 2018-05-26 | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
Country Status (20)
Country | Link |
---|---|
US (3) | US11279675B2 (es) |
EP (1) | EP3630726B1 (es) |
JP (3) | JP7166292B2 (es) |
KR (1) | KR102611445B1 (es) |
CN (1) | CN110621662B (es) |
AU (1) | AU2018272088C1 (es) |
CA (1) | CA3060370A1 (es) |
DK (1) | DK3630726T3 (es) |
EA (1) | EA039654B1 (es) |
ES (1) | ES2909390T3 (es) |
HU (1) | HUE058196T2 (es) |
IL (1) | IL270780A (es) |
MA (1) | MA48776A (es) |
MX (1) | MX2019012505A (es) |
PL (1) | PL3630726T3 (es) |
PT (1) | PT3630726T (es) |
SG (1) | SG11201909161PA (es) |
UA (1) | UA127760C2 (es) |
WO (1) | WO2018218233A1 (es) |
ZA (1) | ZA201906127B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110621662B (zh) | 2017-05-26 | 2023-06-23 | 埃克塞里艾克西斯公司 | 一种盐的结晶性固体形式、制备工艺和使用方法 |
KR20200115582A (ko) | 2018-01-26 | 2020-10-07 | 엑셀리시스, 인코포레이티드 | 키나제-의존성 장애의 치료용 화합물 |
MX2021014773A (es) * | 2019-06-03 | 2022-01-18 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas. |
WO2023165948A1 (en) | 2022-03-01 | 2023-09-07 | Synthon B.V. | Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof |
US11814356B1 (en) | 2023-03-29 | 2023-11-14 | Apotex Inc. | Salt of cabozantinib |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2213661T1 (sl) * | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
US9724342B2 (en) | 2010-07-16 | 2017-08-08 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
KR20230158644A (ko) | 2011-02-10 | 2023-11-20 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
BR112014006702A2 (pt) | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
WO2013066296A1 (en) | 2011-10-31 | 2013-05-10 | Hewlett-Packard Development Company, L.P. | Method of fabricating a color filter array using a multilevel structure |
JP2014532766A (ja) | 2011-11-08 | 2014-12-08 | エクセリクシス, インク. | 癌を治療する、met及びvegfの二重阻害剤 |
AU2012335750A1 (en) | 2011-11-08 | 2014-06-05 | Exelixis, Inc. | Method of quantifying cancer treatment |
CN104649969B (zh) | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
JP6756617B2 (ja) * | 2014-02-14 | 2020-09-16 | エグゼリクシス, インコーポレイテッド | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 |
US9815789B2 (en) * | 2014-05-23 | 2017-11-14 | Mylan Laboratories, Ltd. | Polymorphs of cabozantinib (S)-malate and cabozantinib free base |
CN104961680B (zh) | 2014-11-07 | 2017-09-12 | 苏州晶云药物科技有限公司 | N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型 |
CN104961681B (zh) | 2014-11-13 | 2017-06-13 | 苏州晶云药物科技有限公司 | 卡博替尼的粘酸盐及其晶型 |
WO2016150963A1 (en) * | 2015-03-25 | 2016-09-29 | Sandoz Ag | Cabozantinib salts and their use as anti-cancer agents |
WO2016150966A1 (en) | 2015-03-25 | 2016-09-29 | Sandoz Ag | Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride |
CN109922790B (zh) * | 2016-09-12 | 2022-06-14 | 珠海贝海生物技术有限公司 | 卡博替尼制剂 |
WO2018104954A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof |
CN110621662B (zh) | 2017-05-26 | 2023-06-23 | 埃克塞里艾克西斯公司 | 一种盐的结晶性固体形式、制备工艺和使用方法 |
-
2018
- 2018-05-26 CN CN201880027861.5A patent/CN110621662B/zh active Active
- 2018-05-26 SG SG11201909161P patent/SG11201909161PA/en unknown
- 2018-05-26 JP JP2019562380A patent/JP7166292B2/ja active Active
- 2018-05-26 CA CA3060370A patent/CA3060370A1/en active Pending
- 2018-05-26 AU AU2018272088A patent/AU2018272088C1/en active Active
- 2018-05-26 EP EP18732548.5A patent/EP3630726B1/en active Active
- 2018-05-26 MA MA048776A patent/MA48776A/fr unknown
- 2018-05-26 MX MX2019012505A patent/MX2019012505A/es unknown
- 2018-05-26 HU HUE18732548A patent/HUE058196T2/hu unknown
- 2018-05-26 UA UAA201912198A patent/UA127760C2/uk unknown
- 2018-05-26 DK DK18732548.5T patent/DK3630726T3/da active
- 2018-05-26 ES ES18732548T patent/ES2909390T3/es active Active
- 2018-05-26 EA EA201992803A patent/EA039654B1/ru unknown
- 2018-05-26 US US16/617,352 patent/US11279675B2/en active Active
- 2018-05-26 PT PT187325485T patent/PT3630726T/pt unknown
- 2018-05-26 WO PCT/US2018/034784 patent/WO2018218233A1/en active Application Filing
- 2018-05-26 KR KR1020197031409A patent/KR102611445B1/ko active IP Right Grant
- 2018-05-26 PL PL18732548T patent/PL3630726T3/pl unknown
-
2019
- 2019-09-17 ZA ZA2019/06127A patent/ZA201906127B/en unknown
- 2019-11-20 IL IL270780A patent/IL270780A/en unknown
-
2022
- 2022-02-09 US US17/668,098 patent/US11731941B2/en active Active
- 2022-08-09 JP JP2022127094A patent/JP7437460B2/ja active Active
-
2023
- 2023-06-29 US US18/344,267 patent/US20240010621A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018527A patent/JP2024036690A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
IL270780A (en) | Crystalline solid forms of salts of N-{4-[(7,6-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, processes for preparation and methods of use | |
IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
RS52754B (en) | MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT | |
MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
IL241577B (en) | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide | |
EP3551612A4 (en) | PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE | |
PH12016502461A1 (en) | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts | |
MA49696A (fr) | Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation | |
HK1259405A1 (zh) | N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
IL271399A (en) | Methods for the preparation of heterocyclic 3,1-benzodioxole compounds | |
MA44672A (fr) | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate | |
IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
IL260665B (en) | Improved process for the preparation of osimertinib (azd9291) or its salt and "azd9291 aniline" or its salt | |
WO2018125880A8 (en) | Nrf2 activator | |
ZA202200964B (en) | Salts of a compound, crystal forms of the salts and preparation method and use thereof | |
IL290625A (en) | Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use | |
EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
CO2017009662A2 (es) | Formas cristalinas de un compuesto de pirrolopiridina | |
IL288158A (en) | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
SG11201701674RA (en) | Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | |
SG11202009262VA (en) | Salts of compounds and crystals thereof | |
EP3856732C0 (en) | PROCESS AND SALTS FOR THE PREPARATION OF 2,5-FURANEDICARBOXYLIC ACID | |
PL3898612T3 (pl) | Podstawione pirydynyloksybenzeny, ich sole oraz zastosowanie jako aktywne składniki herbicydowe | |
HUP1800397A2 (en) | Process for the preparation of lumateperone and salts thereof |